How Alendronate (Fosamax) Affects DEXA Bone Density Scores

What Alendronate Does to Bone Density on DEXA

Alendronate reliably increases bone mineral density as measured by dual-energy X-ray absorptiometry (DEXA). The drug does not lower bone density. Every major randomized trial of alendronate in postmenopausal osteoporosis has shown a net positive change in BMD at both the spine and hip compared with placebo.

The Fracture Intervention Trial (FIT), published in JAMA in 1998 and enrolling 2,027 postmenopausal women with at least one vertebral fracture, demonstrated that alendronate 5 to 10 mg daily increased lumbar spine BMD by 6.2% and total hip BMD by 4.1% over 36 months compared with placebo 1. The placebo group lost approximately 0.5 to 1.0% BMD at the spine during the same period.

A 10-year extension of the FIT trial (the FLEX study) confirmed that BMD gains persisted through a full decade of continuous therapy 2. Women who continued alendronate for 10 years gained 13.7% cumulative BMD at the lumbar spine relative to their original baseline. Those who switched to placebo after five years retained most of the hip BMD they had gained, though spine BMD declined modestly.

The size of the BMD response depends on the skeletal site. Trabecular bone (predominant in the spine) responds more than cortical bone (predominant in the femoral shaft). This site-specific difference explains why DEXA gains at the lumbar spine consistently exceed those at the hip or forearm 3.

How Alendronate Changes Bone at the Cellular Level

Alendronate is a nitrogen-containing bisphosphonate that binds to hydroxyapatite on bone surfaces undergoing active resorption. Once osteoclasts internalize the drug during normal bone turnover, alendronate inhibits farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway 4. This disrupts the osteoclast cytoskeleton, reduces acid secretion into the resorption lacuna, and triggers osteoclast apoptosis.

The net result: bone resorption slows dramatically while bone formation continues at a reduced but still active rate. The imbalance favors net mineral deposition.

Bone turnover markers reflect this shift within weeks. Serum C-terminal telopeptide (CTX), a resorption marker, drops 60 to 70% within 3 months of starting alendronate 70 mg weekly 5. Bone-specific alkaline phosphatase (BSAP), a formation marker, decreases 30 to 40% by 6 months, confirming that both arms of remodeling slow down but resorption is suppressed more than formation. That differential is what drives the measurable DEXA increase.

One detail is worth stating plainly. Alendronate does not create new bone architecture. It fills in existing remodeling spaces with mineral and prevents the removal of existing bone. The density gain on DEXA reflects this mineralization rather than the formation of entirely new trabecular struts.

Timeline: When BMD Changes Appear on DEXA

Most clinicians will not see a meaningful DEXA change before 12 months of therapy. The reason is precision.

DEXA scanners have a least significant change (LSC) of approximately 3 to 5% at the lumbar spine, depending on the machine and technologist 6. A 2% gain at 6 months may be real, but it falls within the measurement error of most scanners. By 12 to 18 months, the typical alendronate-treated patient has gained enough BMD to exceed the LSC and show a statistically confident increase.

The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend the first follow-up DEXA scan one to two years after initiating bisphosphonate therapy 7. Repeating the scan sooner risks misinterpreting measurement noise as a treatment failure.

A practical timeline for BMD response looks like this:

• Months 0, 3: Bone resorption markers (CTX) drop 60 to 70%. No DEXA change detectable.
• Months 3, 6: Formation markers (BSAP) decline 30 to 40%. DEXA may show a small gain, but it is within the scanner's margin of error.
• Months 6, 12: BMD increases 2 to 4% at the spine. This change approaches the LSC threshold at well-calibrated centers.
• Months 12, 24: BMD gain reaches 4 to 6% at the spine, 2 to 3% at the hip. The first follow-up DEXA scan is appropriate here.
• Years 3, 5: Cumulative spine BMD gain of 6 to 8%. Rate of gain slows but remains positive.
• Years 5, 10: Continued but smaller annual increments of approximately 0.5 to 1.0% per year at the spine with ongoing therapy.

How Much DEXA Improvement to Expect

The magnitude of BMD increase on alendronate depends on the patient's starting bone density, adherence, calcium and vitamin D status, and the skeletal site measured. Trial data provide useful benchmarks.

In FIT, women with existing vertebral fractures (the vertebral fracture arm) gained a mean of 6.2% at the lumbar spine over 3 years 1. The clinical fracture arm of FIT, which enrolled women with low femoral neck BMD but without baseline vertebral fractures, showed a spine BMD gain of 5.4% over 4 years 8.

The FOSIT trial (N=1,908) examined alendronate 10 mg daily in postmenopausal women across 34 countries and reported a 4.9% increase in lumbar spine BMD at 12 months compared with 0.0% in the placebo group 9. That single-year result confirms the bulk of the response occurs early.

Post-hoc analyses from the FIT data showed that patients with the lowest baseline T-scores tended to gain the most absolute BMD 1. A patient starting with a spine T-score of -3.5 may see a larger percentage gain than one starting at -2.0, though both benefit from fracture risk reduction.

The Endocrine Society's 2019 clinical practice guideline notes that a BMD increase of 3 to 5% at the spine over 3 years is a "typical expected response" to oral bisphosphonate therapy, and that failure to gain at least this much should prompt evaluation for secondary causes of bone loss or adherence issues 10.

Does a Bigger DEXA Gain Mean Fewer Fractures?

Not in a simple linear way. The relationship between BMD gain and fracture reduction on alendronate is real but only partially explains the drug's benefit.

In FIT, alendronate reduced clinical vertebral fractures by 47% and hip fractures by 51% over 3 years 1. A post-hoc analysis published in the Journal of Bone and Mineral Research estimated that only 16% of the vertebral fracture risk reduction could be explained by the change in BMD 11. The remaining benefit comes from improvements in bone quality that DEXA cannot measure, including filling of remodeling spaces, increased mineralization uniformity, and reduced cortical porosity.

This means two things for patients monitoring their DEXA scans. First, a modest gain (for instance, 3% at the spine) still indicates a meaningful fracture risk reduction. Second, a stable BMD (no loss, no gain) on alendronate is not a treatment failure. The drug may still be preventing fractures through mechanisms invisible to DEXA.

Dr. Dennis Black, the lead investigator of the FIT trial, has stated: "Changes in BMD explain only a fraction of the fracture reduction. Patients and clinicians should not rely on DEXA changes alone to judge whether a bisphosphonate is working" 11.

When DEXA Does Not Improve on Alendronate

A minority of patients show stable or declining BMD despite consistent alendronate use. Before labeling the treatment a failure, several factors require evaluation.

Adherence is the most common culprit. Alendronate must be taken on an empty stomach with plain water, 30 minutes before food or other medications. Anything else in the stomach, including coffee, juice, or calcium supplements, reduces absorption to near zero 12. The drug's oral bioavailability is only 0.6% even under ideal conditions. Small deviations from the dosing protocol reduce it further.

Secondary causes of bone loss can overwhelm the effect of alendronate. These include vitamin D deficiency (serum 25-hydroxyvitamin D <20 ng/mL), undiagnosed hyperparathyroidism, celiac disease, hyperthyroidism, chronic glucocorticoid use, and multiple myeloma 10. The AACE guidelines recommend checking serum calcium, 25-hydroxyvitamin D, PTH, TSH, CBC, and serum protein electrophoresis in any patient whose BMD declines on bisphosphonate therapy 7.

Scanner variability also matters. Switching DEXA machines or facilities between baseline and follow-up introduces comparison error that can mask real gains or manufacture false declines. The International Society for Clinical Densitometry (ISCD) recommends that follow-up scans be performed on the same machine by the same technologist whenever possible 6.

If BMD declines by more than the LSC (typically >3 to 5% at the spine) after 18 to 24 months of verified adherent therapy with adequate vitamin D, the clinician should consider switching to a different agent such as denosumab, teriparatide, or romosozumab 10.

Monitoring DEXA on Long-Term Alendronate Therapy

For the first five years, repeat DEXA scans every one to two years to confirm an adequate BMD response and guide treatment decisions 7.

After five years of oral alendronate, both the AACE and the American College of Physicians recommend reassessing whether to continue or take a bisphosphonate holiday 13. The FLEX extension study showed that women who stopped alendronate after five years lost BMD slowly (about 2 to 3% at the spine over 5 years off therapy) but maintained a lower fracture risk than women who had never been treated 2. This residual protection reflects the long skeletal half-life of alendronate, estimated at over 10 years due to the drug's incorporation into the bone mineral matrix 4.

During a drug holiday, DEXA monitoring every two to three years is reasonable. The AACE suggests restarting therapy if the T-score falls below -2.5, a new fracture occurs, or bone turnover markers rise significantly toward pretreatment levels 7.

Patients at high fracture risk (T-score <-3.0, prior vertebral fracture, or age >75 with a hip T-score below -2.5) are generally not candidates for a drug holiday and should continue therapy or switch to an anabolic agent 10.

Alendronate DEXA Results Compared With Other Osteoporosis Drugs

Alendronate's BMD effect is moderate within the spectrum of available treatments. Anabolic agents produce larger gains: teriparatide (Forteo) increases spine BMD by 9 to 13% over 18 to 24 months 14, and romosozumab (Evenity) increases spine BMD by 13.3% in 12 months 15. Denosumab (Prolia), a RANKL inhibitor, achieves 8.8% spine BMD gain at 3 years 16.

Among the oral bisphosphonates, alendronate and risedronate produce similar BMD gains. A head-to-head trial (FACT study, N=1,053) found alendronate 70 mg weekly increased hip trochanter BMD by 3.4% versus 2.0% for risedronate 35 mg weekly at 12 months, a statistically significant difference favoring alendronate 17.

Dr. Felicia Cosman, former chair of the National Osteoporosis Foundation Clinical Committee, has noted: "For most patients with moderate-risk osteoporosis, oral alendronate remains a first-line option because it offers meaningful BMD improvement, proven fracture reduction, and a well-characterized safety profile over decades of use" 10.

Zoledronic acid (Reclast), an intravenous bisphosphonate given once yearly, may be preferred when oral bisphosphonate adherence is poor or when gastrointestinal side effects preclude oral dosing. In the HORIZON trial (N=7,765), zoledronic acid increased lumbar spine BMD by 6.7% over 3 years 18.